NetworkNewsBreaks

WednesdayFeb 15, 2023 12:07 pm

NetworkNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Completes Strategic Sale of Alta Mesa Project

Energy Fuels (NYSE American: UUUU) (TSX: EFR) today announced its completion of the sale of three wholly owned subsidiaries that together hold its Alta Mesa ISR Project to enCore Energy Corp. “Energy Fuels’ sale of the Alta Mesa project for $120 million of total consideration is highly strategic for a variety of reasons,” said UUUU CEO and President Mark S. Chalmers. “When combined with our already strong balance sheet, the proceeds from this sale are expected to fully fund our current uranium, vanadium and rare earth business plans through approximately 2024 without the dilution to shareholders one might normally expect,…

Continue Reading

WednesdayFeb 15, 2023 11:50 am

NetworkNewsBreaks – Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) Complete Road Construction, Start Drilling at the Western Target

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF), based in Arizona and focused on copper and gold exploration, announced that it has completed road construction to the first of two drill pads at the Western Target of the company’s Kay Mine Project. According to the announcement, these pads will allow for testing of the Western Target and drilling of anomalies located between the Central and Western Targets. In the announcement, the company also noted that the Central Target is thought to be a structural repetition of the Kay Mine Deposit horizon. As of Sept. 2022, Arizona Metals has $58 million in…

Continue Reading

WednesdayFeb 15, 2023 11:17 am

NetworkNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Releases Q1 2023 Fiscal, Business Report

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is reporting on its fiscal first quarter for the period ending Dec. 31, 2022. Highlights of the report include the following: acquiring the assets of Electric Last Mile Solutions (“ELMS”) in a $105 million acquisition move; $100 million in cash being available for operations and investment at the end of Q1 2023;  31, 2022; securing the rights for exclusive sales, distribution and branding for the new compact electric vehicle, the Mullen-GO (formerly I-GO), and initial delivery of the vehicle to the distribution agent; receiving a $200 million purchase order from…

Continue Reading

WednesdayFeb 15, 2023 10:57 am

NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Report, Corporate Update for Q3

India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) is reporting on its financial and corporate performance for the third fiscal quarter 2023. Highlights of the report include a focus on the company’s phase 2 clinical trial on IGC-AD1 for agitation in dementia from Alzheimer’s disease. The company reports that the number of sites participating in the trial has reached four: three sites in the United States and one site in Canada. In addition, based on patient enrollment and interest in the study, the company plans to more than double the number of trial sites, from the planned 4 or…

Continue Reading

TuesdayFeb 14, 2023 1:10 pm

NetworkNewsBreaks – Cürex Group Holdings LLC. Announces Additional Bank Participation to Buy-Side, Peer-to Peer Matching Platform

The Cürex Group, a New York City-based institutional foreign exchange execution services and data analytics company, has added Societe Generale to its peer-to-peer matching platform. The company made the announcement, noting that it is growing the platform through increased client participation, trading volume and added connectivity to bank trading algorithms. According to the announcement, the addition enables Cürex’s buy-side clients to seamlessly execute their FX trades in the peer-to-peer pool; they can do this through the trading algorithms of seven major FX banks. In addition, the company noted that it anticipates adding more banks to the platform in coming months. “Our…

Continue Reading

TuesdayFeb 14, 2023 1:07 pm

NetworkNewsBreaks – IBN to Shine the Spotlight on Health Equity in Clinical Trials Congress

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced its collaboration with Kisaco Research for its upcoming Health Equity in Clinical Trials Congress, which is slated to take place at the beautiful Hilton Boston Back Bay on Feb. 22-23, 2023. Kisaco is a leader in combining state-of-the-art conference production with high-impact networking to drive conversations between marquee organizations, policymakers, academic institutions, medtech and biopharma companies. The upcoming event aims to help facilitate change for underrepresented communities through industry action and technology across the animal health, beauty, health and wellness, AI and tech, drug development, women’s health, legal…

Continue Reading

TuesdayFeb 14, 2023 12:53 pm

NetworkNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Schedules Release of Q4 and FY 2022 Financial Results, Earnings Call

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that it will provide a business update and release its financial results for the fourth quarter and full year 2022 following the close of the market on Tuesday, March 14, 2023. Cepton will host a conference call and webcast at 2:30 p.m. PT (5:30 p.m. ET) that same day. Interested parties may join the call by dialing 1-877-300-8521 (toll-free) or 1-412-317-6026 (international) and visiting Cepton’s Investor Relations page to access the live webcast. A telephonic replay will be available approximately two hours after the live…

Continue Reading

TuesdayFeb 14, 2023 11:53 am

NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxt’s second program, AditxtScore(TM), through future strategic revenue and growth-oriented transactions. According to the update, Anthony Voorhies, currently the head of the AditxtScore(TM) division, will serve as president of Pearsanta. Voorhies has over 20 years of clinical diagnostics and healthtech industry experience and, under his leadership, the AditxtScore(TM) division has successfully grown from inception to commercialization and revenues in just…

Continue Reading

TuesdayFeb 14, 2023 11:42 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse. “Alcohol intoxication is a common presentation in many patients who visit hospital emergency rooms, and I see this during every one of my shifts,” said Dr. Albert Wong, a member of FSD Pharma’s expert advisory committee and a psychiatrist in the emergency department at the Centre…

Continue Reading

TuesdayFeb 14, 2023 11:32 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its third quarter performance as well as recent business highlights; the report is for the period ended Dec. 31, 2022. In the report, the company noted that it had received approval from an independent ethics committee in the Netherlands to begin the first-in-human dosing of its CYB004 through a protocol amendment to its ongoing phase 1 CYB004-E trial; CYB004 is the company’s proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule. The company is also making progress on its phase 1/2a clinical trial evaluating CYB003 for the potential treatment…

Continue Reading